US FDA's Marks: Gene Therapy Success Could Hinge On Regulatory Convergence
Executive Summary
Biologics center's director encourages sponsors to invite other regulators to early FDA meetings in effort to scale up markets.
You may also be interested in...
WHO Drafting Regulatory Convergence White Paper On Cell And Gene Therapies, US FDA's Marks Says
Regulators in high-income countries have a responsibility to help health authorities in low- and medium- income countries develop regulatory frameworks for cell and gene therapy products to ensure these treatments are available to all, asserts the US FDA’s biologics center’s director.
Gene Therapy Manufacturing Hitch Solved, Bluebird Aims For European Debut In 2020
The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment
CBER Implements Pre-Clinical Meeting Program For Biologics, Gene Therapy Sponsors
INTERACT program will allow sponsors to ask FDA questions about manufacturing and other technical issues to help streamline development.